Anti-Thyroglobulin IgG in Therapeutic Immunoglobulins: A Reactivity Bias in IgG4 Subclass


Therapeutic immunoglobulins are used in the treatment of immunodeficiencies as well as several autoimmune and inflammatory diseases. These intravenous immunoglobulins (IVIg) represent the healthy human IgG repertoire, which can be reactive for both self and non-self antigens. A better characterization of IVIg’s repertoire is an important aspect to enable its effective utilization as an immunomodulatory treatment. In this study we have investigated the reactivity of IgG1, IgG2, IgG3 and IgG4 present in IVIg for a small selection of antigens, including actin, DNA, ferritin and thyroglobulin. We observed that two commercial preparations of therapeutic immunoglobulins contain very high reactivity for thyroglobulin, which was predominantly detected by IgG4. Since IgG4 antibodies can have immunomodulatory properties, these result suggest that these anti-thyroglobulin may have a role in the IVIg treatment of autoimmune disease characterized by high avidity for anti-thyroglobulin antibodies such as Hashimoto’s disease.

Share and Cite:

Néron, S. , Roy, A. , Dussault, N. and Philipeau, C. (2014) Anti-Thyroglobulin IgG in Therapeutic Immunoglobulins: A Reactivity Bias in IgG4 Subclass. Open Journal of Immunology, 4, 68-75. doi: 10.4236/oji.2014.43010.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] Schwab, I. and Nimmerjahn, F. (2013) Intravenous Immunoglobulin Therapy: How Does IgG Modulate the Immune System? Nature Review Immunology, 13, 176-189.
[2] Gelfand, E.W. (2012) Intravenous Immune Globulin in Autoimmune and Inflammatory Diseases. New England Journal of Medicine, 367, 2015-2025.
[3] Aschermann, S., Lux, A., Baerenwaldt, A., Biburger, M. and Nimmerjahn, F. (2010) The Other Side of Immunoglobulin G: Suppressor of Inflammation. Clinical and Experimental Immunology, 160, 161-167.
[4] Salfeld, J.G. (2007) Isotype Selection in Antibody Engineering. Nature Biotechnology, 25, 1369-1372.
[5] von Gunten, S., Smith, D.F., Cummings, R.D., Riedel, S., Miescher, S., Schaub, A., Hamilton, R.G. and Bochner, B.S. (2009) Intravenous Immunoglobulin Contains a Broad Repertoire of Anticarbohydrate Antibodies That Is Not Restricted to the IgG(2) Subclass. Journal of Allergy and Clinical Immunology, 123, 1268-1276.
[6] van der Neut Kolfschoten, M., Schuurman, J., Losen, M., et al. (2007) Anti-Inflammatory Activity of Human IgG4 Antibodies by Dynamic Fab Arm Exchange. Science, 317, 1554-1557.
[7] Burton, D.R. and Wilson, I.A. (2007) Immunology. Square-Dancing Antibodies. Science, 317, 1507-1508.
[8] Rispens, T., Ooijevaar-de Heer, P., Bende, O. and Aalberse, R.C. (2011) Mechanism of Immunoglobulin G4 Fab-Arm Exchange. Journal of the American Chemical Society, 133, 10302-10311.
[9] Nirula, A., Glaser, S.M., Kalled, S.L. and Taylor, F.R. (2011) What Is IgG4? A Review of the Biology of a Unique Immunoglobulin Subtype. Current Opinion in Rheumatology, 23, 119-124.
[10] Wang, W. and Li, J. (2011) Identification of Natural Bispecific Antibodies against Cyclic Citrullinated Peptide and Immunoglobulin G in Rheumatoid Arthritis. PLoS One, 6, e16527.
[11] Ebbo, M., Daniel, L., Pavic, M., et al. (2012) IgG4-Related Systemic Disease: Features and Treatment Response in a French Cohort: Results of a Multicenter Registry. Medicine, 91, 49-56.
[12] Ebbo, M., Grados, A., Daniel, L., Vely, F., Harle, J.R., Pavic, M. and Schleinitz, N. (2012) IgG4-Related Systemic Disease: Emergence of a New Systemic Disease? Literature Review. La Revue de Médecine Interne, 33, 23-34.
[13] Zen, Y. and Nakanuma, Y. (2010) IgG4-Related Disease: A Cross-Sectional Study of 114 Cases. American Journal of Surgical Pathology, 34, 1812-1819.
[14] Maehara, T., Moriyama, M., Nakashima, H., Miyake, K., Hayashida, J.N., Tanaka, A., Shinozaki, S., Kubo, Y. and Nakamura, S. (2012) Interleukin-21 Contributes to Germinal Centre Formation and Immunoglobulin G4 Production in IgG4-Related Dacryoadenitis and Sialoadenitis, So-Called Mikulicz’S Disease. Annals of the Rheumatic Diseases, 71, 2011-2020.
[15] von Gunten, S., Schaub, A., Vogel, M., Stadler, B.M., Miescher, S. and Simon, H.U. (2006) Immunologic and Functional Evidence for Anti-Siglec-9 Autoantibodies in Intravenous Immunoglobulin Preparations. Blood, 108, 4255-4259.
[16] Gelfand, E.W. (2001) Antibody-Directed Therapy: Past, Present, and Future. Journal of Allergy and Clinical Immunology, 108, S111-S116.
[17] Sewell, W.A.C. and Jolles, S. (2002) Immunomodulatory Action of Intravenous Immunoglobulin. Immunology, 107, 387-393.
[18] Lamoureux, J., Aubin, E. and Lemieux, R. (2004) Autoantibodies Purified from Therapeutic Preparations of Intravenous Immunoglobulins (IVIg) Induce the Formation of Autoimmune Complexes in Normal Human Serum: A Role in the in Vivo Mechanisms of Action of IVIg? International Immunology, 16, 929-936.
[19] Dimitrov, J.D., Planchais, C., Kang, J., Pashov, A., Vassilev, T.L., Kaveri, S.V. and Lacroix-Desmazes, S. (2010) Heterogeneous Antigen Recognition Behavior of Induced Polyspecific Antibodies. Biochemical and Biophysical Research Communications, 398, 266-271.
[20] Bussone, G., Dib, H., Dimitrov, J.D., Camoin, L., Broussard, C., Tamas, N., Guillevin, L., Kaveri, S.V. and Mouthon, L. (2009) Identification of Target Antigens of Self-Reactive IgG in Intravenous Immunoglobulin Preparations. Proteomics, 9, 2253-2262.
[21] Schaub, A., Wymann, S., Heller, M., Ghielmetti, M., Beleznay, Z., Stadler, B.M., Bolli, R. and Miescher, S. (2007) Self-Reactivity in the Dimeric Intravenous Immunoglobulin Fraction. Annals of the New York Academy of Sciences, 1110, 681-693.
[22] Néron, S. and Roy, A. (2012) Overview of IgG-Reactivity in Therapeutic Immunoglobulins Revealed by Protein Array Analysis. Biochemistry & Analytical Biochemistry, S8, 001.
[23] Ballow, M. (2011) The IgG Molecule as a Biological Immune Response Modifier: Mechanisms of Action of Intravenous Immune Serum Globulin in Autoimmune and Inflammatory Disorders. Journal of Allergy and Clinical Immunology, 127, 315-323.
[24] Tha-In, T., Bayry, J., Metselaar, H.J., Kaveri, S.V. and Kwekkeboom, J. (2008) Modulation of the Cellular Immune System by Intravenous Immunoglobulin. Trends in Immunology, 29, 608-615.
[25] de Grandmont, M.J., Racine, C., Roy, A., Lemieux, R. and Néron, S. (2003) Intravenous Immunoglobulins Induce the in Vitro Differentiation of Human B Lymphocytes and the Secretion of IgG. Blood, 101, 3065-3073.
[26] Siegel, J. (2005) Immune Globulins: Therapeutic, Pharmaceutical, Cost, and Administration Considerations. Pharmacy Practice News, Special Edition, 15-19.
[27] Kaushik, A., Lim, A., Poncet, P., Ge, X.R. and Dighiero, G. (1988) Comparative Analysis of Natural Antibody Specificities among Hybridomas Originating from Spleen and Peritoneal Cavity of Adult NZB and BALB/c Mice. Scandinavian Journal of Immunology, 27, 461-471.
[28] Li, Y., Nishihara, E. and Kakudo, K. (2011) Hashimoto’s Thyroiditis: Old Concepts and New Insights. Current Opinion in Rheumatology, 23, 102-107.
[29] Adler, T.R., Beall, G.N., Curd, J.G., Heiner, D.C. and Sabharwal, U.K. (1984) Studies of Complement Activation and IgG Subclass Restriction of Anti-Thyroglobulin. Clinical and Experimental Immunology, 56, 383-389.
[30] Liu, W., Meckel, T., Tolar, P., Sohn, H.W. and Pierce, S.K. (2010) Intrinsic Properties of Immunoglobulin IgG1 Isotype-Switched B Cell Receptors Promote Microclustering and the Initiation of Signaling. Immunity, 32, 778-789.
[31] Xie, L.-D., Gao, Y., Li, M.-R., Lu, G.Z. and Guo, X.-H. (2008) Distribution of Immunoglobulin G Subclasses of Anti- Thyroid Peroxidase Antibody in Sera from Patients with Hashimoto’s Thyroiditis with Different Thyroid Functional Status. Clinical & Experimental Immunology, 154, 172-176.
[32] Zhang, Y., Gao, Y., Li, M., Xie, L., Huang, Y. and Guo, X. (2010) Avidity of Thyroglobulin Antibody in Sera from Patients with Hashimoto’s Thyroiditis with Different Thyroid Functional Status. Clinical and Experimental Immunology, 161, 65-70.
[33] Dietrich, G. and Kazatchkine, M.D. (1990) Normal Immunoglobulin G (IgG) for Therapeutic Use (Intravenous Ig) Contain Antiidiotypic Specificities against an Immunodominant, Disease-Associated, Cross-Reactive Idiotype of Human Anti-Thyroglobulin Autoantibodies. The Journal of Clinical Investigations, 85, 620-625.
[34] Dietrich, G., Piechaczyk, M., Pau, B. and Kazatchkine, M.D. (1991) Evidence for a Restricted Idiotypic and Epitopic Specificity of Anti-Thyroglobulin Autoantibodies in Patients with Autoimmune Thyroiditis. European Journal of Immunology, 21, 811-814.
[35] Dietrich, G., Varela, F.J., Hurez, V., Bouanani, M. and Kazatchkine, M.D. (1993) Selection of the Expressed B Cell Repertoire by Infusion of Normal Immunoglobulin G in a Patient with Autoimmune Thyroiditis. European Journal of Immunology, 23, 2945-2950.
[36] Rossi, F. and Kazatchkine, M.D. (1989) Antiidiotypes against Autoantibodies in Pooled Normal Human Polyspecific Ig. The Journal of Immunology, 143, 4104-4109.
[37] Nezlin, R. (2010) Interactions between Immunoglobulin G Molecules. Immunology Letters, 132, 1-5.
[38] Aalberse, R.C., Stapel, S.O., Schuurman, J. and Rispens, T. (2009) Immunoglobulin G4: An Odd Antibody. Clinical and Experimental Allergy, 39, 469-477.
[39] Rispens, T., Ooievaar-De Heer, P., Vermeulen, E., Schuurman, J., van der Neut Kolfschoten, M. and Aalberse, R.C. (2009) Human IgG4 Binds to IgG4 and Conformationally Altered IgG1 via Fc-Fc Interactions. The Journal of Immunology, 182, 4275-4281.
[40] Lamoureux, J., Aubin, E. and Lemieux, R. (2003) Autoimmune Complexes in Human Serum in Presence of Therapeutic Amounts of Intravenous Immunoglobulins. Blood, 101, 1660-1662.

Copyright © 2023 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.